Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis

Mayo Clinic

Status and phase: Completed; Phase 2; Phase 1

Conditions: Amyloidosis

Treatments: Other: 18-F Florbetapir PET/MR scan

Study type: Interventional

Funder types: Other

Identifiers

NCT03019029

16-006798

Details and patient eligibility

About

The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid diseased controls.

Full description

Patients with pathologically proven amyloidosis involving the peripheral nervous system will undergo 18-F Florbetapir PET/MR on a GE (General Electric Healthcare) SIGNA PET/MR scanner. A control arm comprised of patients with pathologically-confirmed non-amyloid causes of peripheral neuropathy will also undergo 18-F Florbetapir PET/MR scanning. all images will be reviewed for peripheral nerve uptake.

Enrollment: 8 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults: 18-100
• Pathologically-confirmed peripheral nerve amyloidosis or pathologically-confirmed non-amyloid causes of peripheral neuropathy

Exclusion criteria

• Metallic devices that are not MR safe (cardiac pacers, stents, aneurysm coils, etc.)
• Claustrophobia
• BMI over 38

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

Peripheral nerve amyloidosis

Experimental group

Description:

Patients with pathologically-confirmed peripheral nerve amyloidosis will undergo 18-F Florbetapir PET/MR scan on a GE SIGNA PET/MR scanner.

Treatment:

Other: 18-F Florbetapir PET/MR scan